

Carien L Creutzberg

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5749826/carien-l-creutzberg-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

137
papers

10,071
citations

50
h-index

99
g-index

149
ext. papers

13,082
ext. citations

5
avg, IF

5.92
L-index

#	Paper	IF	Citations
137	Tertiary lymphoid structures critical for prognosis in endometrial cancer patients.. <i>Nature Communications</i> , 2022 , 13, 1373	17.4	3
136	Vaginal brachytherapy management of stage I and II endometrial cancer.. <i>International Journal of Gynecological Cancer</i> , 2022 , 32, 304-310	3.5	
135	ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. <i>International Journal of Gynecological Cancer</i> , 2021 , 31, 12-39	3.5	203
134	Radiation Therapy Techniques and Treatment-Related Toxicity in the PORTEC-3 Trial: Comparison of 3-Dimensional Conformal Radiation Therapy Versus Intensity-Modulated Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021 ,	4	1
133	Cancer of the corpus uteri: 2021 update. <i>International Journal of Gynecology and Obstetrics</i> , 2021 , 155 Suppl 1, 45-60	4	14
132	PROTECT: Prospective Phase-II-Trial Evaluating Adaptive Proton Therapy for Cervical Cancer to Reduce the Impact on Morbidity and the Immune System. <i>Cancers</i> , 2021 , 13,	6.6	1
131	Prevalence and Prognosis of Lynch Syndrome and Sporadic Mismatch Repair Deficiency in Endometrial Cancer. <i>Journal of the National Cancer Institute</i> , 2021 , 113, 1212-1220	9.7	11
130	Response to: Are we confident treating pT1a G1 lymphovascular space invasion-negative patients (with myometrial invasion) with chemoradiotherapy on the basis of p53abn?. <i>International Journal of Gynecological Cancer</i> , 2021 , 31, 947	3.5	0
129	Red Blood Cell Transfusion Practices for Patients With Cervical Cancer Undergoing Radiotherapy. <i>JAMA Network Open</i> , 2021 , 4, e213531	10.4	1
128	Patients and clinicians preferences in adjuvant treatment for high-risk endometrial cancer: Implications for shared decision making. <i>Gynecologic Oncology</i> , 2021 , 161, 727-733	4.9	1
127	Management of conjunctival melanoma with local excision and adjuvant brachytherapy. <i>Eye</i> , 2021 , 35, 490-498	4.4	3
126	NRG Oncology/RTOG Consensus Guidelines for Delineation of Clinical Target Volume for Intensity Modulated Pelvic Radiation Therapy in Postoperative Treatment of Endometrial and Cervical Cancer: An Update. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021 , 109, 413-424	4	17
125	Adjuvant therapy for endometrial cancer in the era of molecular classification: radiotherapy, chemoradiation and novel targets for therapy. <i>International Journal of Gynecological Cancer</i> , 2021 , 31, 594-604	3.5	15
124	Long-Term Toxicity and Health-Related Quality of Life After Adjuvant Chemoradiation Therapy or Radiation Therapy Alone for High-Risk Endometrial Cancer in the Randomized PORTEC-3 Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021 , 109, 975-986	4	7
123	ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. <i>Radiotherapy and Oncology</i> , 2021 , 154, 327-353	5.3	17
122	ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021 , 478, 153-190	5.1	18
121	Image-Guided Adaptive Brachytherapy (IGABT) for Primary Vaginal Cancer: Results of the International Multicenter RetroEMBRAVE Cohort Study. <i>Cancers</i> , 2021 , 13,	6.6	1

120	Phase II study of definitive chemoradiation for locally advanced squamous cell cancer of the vulva: An efficacy study. <i>Gynecologic Oncology</i> , 2021 , 163, 117-124	4.9	1
119	Radiotherapy Versus Inguinofemoral Lymphadenectomy as Treatment for Vulvar Cancer Patients With Micrometastases in the Sentinel Node: Results of GROINSS-V II. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3623-3632	2.2	12
118	Psychometric validation of the European Organisation for Research and Treatment of Cancer-Quality of Life Questionnaire Sexual Health (EORTC QLQ-SH22). <i>European Journal of Cancer</i> , 2021 , 154, 235-245	7.5	2
117	A sexual rehabilitation intervention for women with gynaecological cancer receiving radiotherapy (SPARC study): design of a multicentre randomized controlled trial. <i>BMC Cancer</i> , 2021 , 21, 1295	4.8	1
116	Prognostic Integrated Image-Based Immune and Molecular Profiling in Early-Stage Endometrial Cancer. <i>Cancer Immunology Research</i> , 2020 , 8, 1508-1519	12.5	14
115	HER2 Status in High-Risk Endometrial Cancers (PORTEC-3): Relationship with Histotype, Molecular Classification, and Clinical Outcomes. <i>Cancers</i> , 2020 , 13,	6.6	9
114	PARP and PD-1/PD-L1 checkpoint inhibition in recurrent or metastatic endometrial cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2020 , 152, 102973	7	9
113	Vulvar cancer subclassification by HPV and p53 status results in three clinically distinct subtypes. <i>Gynecologic Oncology</i> , 2020 , 159, 649-656	4.9	19
112	PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer. <i>International Journal of Gynecological Cancer</i> , 2020 , 30, 2002-2007	3.5	34
111	Efficacy and toxicity of postoperative external beam radiotherapy or chemoradiation for early-stage cervical cancer. <i>International Journal of Gynecological Cancer</i> , 2020 , 30, 1878-1886	3.5	1
110	Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3388-3397	2.2	116
109	Efficacy and toxicity of chemoradiation with image-guided adaptive brachytherapy for locally advanced cervical cancer. <i>International Journal of Gynecological Cancer</i> , 2019 , 29, 257-265	3.5	9
108	Gynecological Cancers Translational, Research Implementation, and Harmonization: Gynecologic Cancer InterGroup Consensus and Still Open Questions. <i>Cells</i> , 2019 , 8,	7.9	4
107	A Transcriptionally Distinct CXCL13CD103CD8 T-cell Population Is Associated with B-cell Recruitment and Neoantigen Load in Human Cancer. <i>Cancer Immunology Research</i> , 2019 , 7, 784-796	12.5	53
106	Uterine Cancer: Adjuvant Therapy and Management of Metastatic Disease. <i>Journal of Clinical Oncology</i> , 2019 , 37, 2490-2500	2.2	10
105	Selecting Adjuvant Treatment for Endometrial Carcinoma Using Molecular Risk Factors. <i>Current Oncology Reports</i> , 2019 , 21, 83	6.3	13
104	Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial. <i>Lancet Oncology</i> , 2019 , 20, 1273-1285	21.7	160
103	Vulvar malignant melanoma: Pathogenesis, clinical behaviour and management: Review of the literature. <i>Cancer Treatment Reviews</i> , 2019 , 73, 91-103	14.4	22

102	Adjuvant therapy for high-risk endometrial cancer: recent evidence and future directions. <i>Expert Review of Anticancer Therapy</i> , 2019 , 19, 51-60	3.5	8
101	Phase 1-3 of the cross-cultural development of an EORTC questionnaire for the assessment of sexual health in cancer patients: the EORTC SHQ-22. <i>Cancer Medicine</i> , 2018 , 7, 635-645	4.8	15
100	Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. <i>Lancet Oncology</i> , 2018 , 19, 295-309	21.7	263
99	Endometrial cancer SURvivorsRfollow-up carE (ENSURE): Less is more? Evaluating patient satisfaction and cost-effectiveness of a reduced follow-up schedule: study protocol of a randomized controlled trial. <i>Trials</i> , 2018 , 19, 227	2.8	11
98	InvestigatorsRresponse. <i>Lancet Oncology</i> , 2018 , 19, 602	21.7	
97	Adjuvant Treatment for Proofreading Domain-Mutant Cancers: Sensitivity to Radiotherapy, Chemotherapy, and Nucleoside Analogues. <i>Clinical Cancer Research</i> , 2018 , 24, 3197-3203	12.9	30
96	STATEC: A randomised trial of non-selective versus selective adjuvant therapy in high risk apparent stage 1 endometrial cancer.. <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS5615-TPS5615	2.2	2
95	International development of four EORTC disease-specific quality of life questionnaires for patients with Hodgkin lymphoma, high- and low-grade non-Hodgkin lymphoma and chronic lymphocytic leukaemia. <i>Quality of Life Research</i> , 2018 , 27, 333-345	3.7	19
94	Ruthenium-106 brachytherapy for iris and iridociliary melanomas. <i>British Journal of Ophthalmology</i> , 2018 , 102, 1154-1159	5.5	4
93	Blinded histopathological characterisation of POLE exonuclease domain-mutant endometrial cancers: sheep in wolfB clothing. <i>Histopathology</i> , 2018 , 72, 248-258	7.3	17
92	ESGO Survey on Current Practice in the Management of Cervical Cancer. <i>International Journal of Gynecological Cancer</i> , 2018 , 28, 1226-1231	3.5	16
91	Cancer of the corpus uteri. <i>International Journal of Gynecology and Obstetrics</i> , 2018 , 143 Suppl 2, 37-50	4	166
90	Differences in health care professionalsRand cancer patientsRviews on sexual health issues. <i>Psycho-Oncology</i> , 2018 , 27, 2299-2302	3.9	1
89	A Controlled Study on Vaginal Blood Flow During Sexual Arousal Among Early-Stage Cervical Cancer Survivors Treated With Conventional Radical or Nerve-Sparing Surgery With or Without Radiotherapy. <i>International Journal of Gynecological Cancer</i> , 2017 , 27, 1051-1057	3.5	6
88	Immunological profiling of molecularly classified high-risk endometrial cancers identifies -mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition. <i>Oncolmunology</i> , 2017 , 6, e1264565	7.2	79
87	Amplification of 1q32.1 Refines the Molecular Classification of Endometrial Carcinoma. <i>Clinical Cancer Research</i> , 2017 , 23, 7232-7241	12.9	19
86	Reply to M. Wissing et al. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1862	2.2	
85	European Society of Gynaecological Oncology (ESGO) Guidelines for Ovarian Cancer Surgery. <i>International Journal of Gynecological Cancer</i> , 2017 , 27, 1534-1542	3.5	62

84	Final results of the international randomized PORTEC-3 trial of adjuvant chemotherapy and radiation therapy (RT) versus RT alone for women with high-risk endometrial cancer.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 5502-5502	2.2	18
83	Limited impact of intratumour heterogeneity on molecular risk assignment in endometrial cancer. <i>Oncotarget</i> , 2017 , 8, 25542-25551	3.3	12
82	Endometrial cancer. <i>Lancet, The</i> , 2016 , 387, 1094-1108	4.0	797
81	Which cervical and endometrial cancer patients will benefit most from intensity-modulated proton therapy?. <i>Radiotherapy and Oncology</i> , 2016 , 120, 397-403	5.3	10
80	Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial. <i>Lancet Oncology, The</i> , 2016 , 17, 1114-1126	21.7	104
79	Patients and clinicians preferences for adjuvant chemotherapy in endometrial cancer: an ANZGOG substudy of the PORTEC-3 intergroup randomised trial. <i>British Journal of Cancer</i> , 2016 , 115, 1179-1185	8.7	15
78	Hyperbaric oxygen therapy for radiation-induced injury: evidence is needed. <i>Lancet Oncology, The</i> , 2016 , 17, 132-134	21.7	6
77	Radiation therapy combined with hyperthermia versus cisplatin for locally advanced cervical cancer: Results of the randomized RADCHOC trial. <i>Radiotherapy and Oncology</i> , 2016 , 120, 378-382	5.3	43
76	Prognostic significance of L1CAM expression and its association with mutant p53 expression in high-risk endometrial cancer. <i>Modern Pathology</i> , 2016 , 29, 174-81	9.8	42
75	Microsatellite instability derived JAK1 frameshift mutations are associated with tumor immune evasion in endometrioid endometrial cancer. <i>Oncotarget</i> , 2016 , 7, 39885-39893	3.3	21
74	ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, Treatment and Follow-up. <i>International Journal of Gynecological Cancer</i> , 2016 , 26, 2-30	3.5	358
73	Results of the Australasian (Trans-Tasman Oncology Group) radiotherapy benchmarking exercise in preparation for participation in the PORTEC-3 trial. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2016 , 60, 554-9	1.7	5
72	Ruthenium-106 brachytherapy for choroidal melanoma without transpupillary thermotherapy: Similar efficacy with improved visual outcome. <i>European Journal of Cancer</i> , 2016 , 68, 106-113	7.5	15
71	European Society of Gynaecologic Oncology Quality Indicators for Advanced Ovarian Cancer Surgery. <i>International Journal of Gynecological Cancer</i> , 2016 , 26, 1354-63	3.5	59
70	Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer-Combined Analysis of the PORTEC Cohorts. <i>Clinical Cancer Research</i> , 2016 , 22, 4215-24	12.9	286
69	Local control rate after the combination of re-irradiation and hyperthermia for irresectable recurrent breast cancer: Results in 248 patients. <i>Radiotherapy and Oncology</i> , 2015 , 117, 217-22	5.3	61
68	Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative. <i>Modern Pathology</i> , 2015 , 28, 836-44	9.8	222
67	Long-Term Impact of Endometrial Cancer Diagnosis and Treatment on Health-Related Quality of Life and Cancer Survivorship: Results From the Randomized PORTEC-2 Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015 , 93, 797-809	4	60

66	Qualitative accounts of patients' determinants of vaginal dilator use after pelvic radiotherapy. <i>Journal of Sexual Medicine</i> , 2015 , 12, 764-73	1.1	22
65	Groin surgery and risk of recurrence in lymph node positive patients with vulvar squamous cell carcinoma. <i>Gynecologic Oncology</i> , 2015 , 139, 458-64	4.9	13
64	Variability in clinical target volume delineation for intensity modulated radiation therapy in 3 challenging cervix cancer scenarios. <i>Practical Radiation Oncology</i> , 2015 , 5, e557-65	2.8	9
63	Radiation Treatment Affects Chromosome Testing in Uveal Melanoma 2015 , 56, 5956-64		23
62	POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer. <i>Clinical Cancer Research</i> , 2015 , 21, 3347-3355	12.9	184
61	Rectal bleeding after radiation therapy for endometrial cancer. <i>Radiotherapy and Oncology</i> , 2015 , 115, 240-5	5.3	6
60	Cancer of the corpus uteri. <i>International Journal of Gynecology and Obstetrics</i> , 2015 , 131 Suppl 2, S96-104		56
59	No Increased Risk of Second Cancer After Radiotherapy in Patients Treated for Rectal or Endometrial Cancer in the Randomized TME, PORTEC-1, and PORTEC-2 Trials. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1640-6	2.2	61
58	ESMO-ESGO-ESTRO consensus conference on endometrial cancer: Diagnosis, treatment and follow-up. <i>Radiotherapy and Oncology</i> , 2015 , 117, 559-81	5.3	131
57	Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer--A pooled analysis of PORTEC 1 and 2 trials. <i>European Journal of Cancer</i> , 2015 , 51, 1742-50	7.5	153
56	Psychosexual support for gynecological cancer survivors: professionals' current practices and need for assistance. <i>Supportive Care in Cancer</i> , 2015 , 23, 831-9	3.9	22
55	Nomograms for prediction of outcome with or without adjuvant radiation therapy for patients with endometrial cancer: a pooled analysis of PORTEC-1 and PORTEC-2 trials. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015 , 91, 530-9	4	38
54	Prognostic significance of POLE proofreading mutations in endometrial cancer. <i>Journal of the National Cancer Institute</i> , 2015 , 107, 402	9.7	169
53	Adjuvant chemotherapy and radiation therapy (RT) versus RT alone for women with high-risk endometrial cancer: Toxicity and quality-of-life results of the randomized PORTEC-3 trial.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 5501-5501	2.2	2
52	Impact of cardiovascular counseling and screening in Hodgkin lymphoma survivors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014 , 90, 164-71	4	3
51	Second primary cancers in survivors of cervical cancer in The Netherlands: Implications for prevention and surveillance. <i>Radiotherapy and Oncology</i> , 2014 , 111, 374-81	5.3	33
50	High concordance of molecular tumor alterations between pre-operative curettage and hysterectomy specimens in patients with endometrial carcinoma. <i>Gynecologic Oncology</i> , 2014 , 133, 197-204	4.9	48
49	Sexual dysfunction and infertility as late effects of cancer treatment. <i>European Journal of Cancer, Supplement</i> , 2014 , 12, 41-53	1.6	123

48	Sexual rehabilitation after pelvic radiotherapy and vaginal dilator use: consensus using the Delphi method. <i>International Journal of Gynecological Cancer</i> , 2014 , 24, 1499-506	3.5	36
47	Gynecologic Cancer InterGroup (GCIg) consensus review for uterine and ovarian carcinosarcoma. <i>International Journal of Gynecological Cancer</i> , 2014 , 24, S55-60	3.5	78
46	Gynecologic Cancer InterGroup (GCIg) consensus review for uterine serous carcinoma. <i>International Journal of Gynecological Cancer</i> , 2014 , 24, S83-9	3.5	39
45	Persisting fatigue in Hodgkin lymphoma survivors: a systematic review. <i>Annals of Hematology</i> , 2013 , 92, 1023-32	3	36
44	Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations, TP53 and microsatellite instability in endometrial cancer. <i>Modern Pathology</i> , 2013 , 26, 1525-35	9.8	132
43	Long-term risk of secondary skin cancers after radiation therapy for Hodgkin lymphoma. <i>Radiotherapy and Oncology</i> , 2013 , 109, 140-5	5.3	10
42	Long-term clinical outcome of patients with soft tissue sarcomas treated with limb-sparing surgery and postoperative radiotherapy. <i>Acta Oncologica</i> , 2013 , 52, 745-52	3.2	19
41	Self-reported sexual, bowel and bladder function in cervical cancer patients following different treatment modalities: longitudinal prospective cohort study. <i>International Journal of Gynecological Cancer</i> , 2013 , 23, 1717-25	3.5	58
40	Screening for coronary artery disease after mediastinal irradiation in Hodgkin lymphoma survivors. <i>Journal of Clinical Oncology</i> , 2013 , 31, 8568-8568	2.2	
39	Ruthenium plaque radiation therapy for iris and iridociliary melanomas. <i>Acta Ophthalmologica</i> , 2012 , 90, 291-6	3.7	17
38	Cancer of the corpus uteri. <i>International Journal of Gynecology and Obstetrics</i> , 2012 , 119 Suppl 2, S110-7	4	32
37	International brachytherapy practice patterns: a survey of the Gynecologic Cancer Intergroup (GCIg). <i>International Journal of Radiation Oncology Biology Physics</i> , 2012 , 82, 250-5	4	124
36	Improved risk assessment of endometrial cancer by combined analysis of MSI, PI3K-AKT, Wnt/βcatenin and P53 pathway activation. <i>Gynecologic Oncology</i> , 2012 , 126, 466-73	4.9	48
35	Five-year quality of life of endometrial cancer patients treated in the randomised Post Operative Radiation Therapy in Endometrial Cancer (PORTEC-2) trial and comparison with norm data. <i>European Journal of Cancer</i> , 2012 , 48, 1638-48	7.5	115
34	Perceived information provision and satisfaction among lymphoma and multiple myeloma survivors—results from a Dutch population-based study. <i>Annals of Hematology</i> , 2012 , 91, 1587-95	3	40
33	Psychometric validation of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Endometrial Cancer Module (EORTC QLQ-EN24). <i>European Journal of Cancer</i> , 2011 , 47, 183-90	7.5	68
32	Normative data for the EORTC QLQ-C30 and EORTC-sexuality items in the general Dutch population. <i>European Journal of Cancer</i> , 2011 , 47, 667-75	7.5	135
31	Fifteen-year radiotherapy outcomes of the randomized PORTEC-1 trial for endometrial carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011 , 81, e631-8	4	204

30	The role of radiotherapy in endometrial cancer: current evidence and trends. <i>Current Oncology Reports</i> , 2011 , 13, 472-8	6.3	32
29	Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy for the definitive treatment of cervix cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011 , 79, 348-55	4	279
28	Long-term outcome and quality of life of patients with endometrial carcinoma treated with or without pelvic radiotherapy in the post operative radiation therapy in endometrial carcinoma 1 (PORTEC-1) trial. <i>Journal of Clinical Oncology</i> , 2011 , 29, 1692-700	2.2	174
27	Point: Vaginal brachytherapy should be a standard adjuvant treatment for intermediate-risk endometrial cancer. <i>Brachytherapy</i> , 2011 , 10, 1-3	2.4	3
26	Efficacy of a hypofractionated schedule in electron beam radiotherapy for epithelial skin cancer: Analysis of 434 cases. <i>Radiotherapy and Oncology</i> , 2010 , 95, 245-9	5.3	60
25	Long-term outcomes of eye-conserving treatment with Ruthenium(106) brachytherapy for choroidal melanoma. <i>Radiotherapy and Oncology</i> , 2010 , 95, 332-8	5.3	50
24	Adjuvant chemotherapy for endometrial cancer: unproven. <i>International Journal of Gynecological Cancer</i> , 2010 , 20, S60-3	3.5	3
23	Adjuvant chemotherapy for endometrial cancer: unproven. <i>International Journal of Gynecological Cancer</i> , 2010 , 20, 1105-8	3.5	8
22	Quality of life after pelvic radiotherapy or vaginal brachytherapy for endometrial cancer: first results of the randomized PORTEC-2 trial. <i>Journal of Clinical Oncology</i> , 2009 , 27, 3547-56	2.2	216
21	Radiotherapy and hyperthermia for treatment of primary locally advanced cervix cancer: results in 378 patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009 , 73, 242-50	4	59
20	Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy in postoperative treatment of endometrial and cervical cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008 , 71, 428-34	4	268
19	Postoperative radiotherapy for Stage 1 endometrial carcinoma: long-term outcome of the randomized PORTEC trial with central pathology review. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005 , 63, 834-8	4	182
18	Lymphadenectomy in apparent early-stage endometrial carcinoma: do numbers count?. <i>Journal of Clinical Oncology</i> , 2005 , 23, 3653-5	2.2	16
17	GOG-99: ending the controversy regarding pelvic radiotherapy for endometrial carcinoma?. <i>Gynecologic Oncology</i> , 2004 , 92, 740-3	4.9	39
16	Prognostic significance and interobserver variability of histologic grading systems for endometrial carcinoma. <i>Cancer</i> , 2004 , 100, 764-72	6.4	99
15	Outcome of high-risk stage IC, grade 3, compared with stage I endometrial carcinoma patients: the Postoperative Radiation Therapy in Endometrial Carcinoma Trial. <i>Journal of Clinical Oncology</i> , 2004 , 22, 1234-41	2.2	221
14	Survival after relapse in patients with endometrial cancer: results from a randomized trial. <i>Gynecologic Oncology</i> , 2003 , 89, 201-9	4.9	290
13	Long-term outcome in endometrial carcinoma favors a two- instead of a three-tiered grading system. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002 , 52, 1067-74	4	32

12	The morbidity of treatment for patients with Stage I endometrial cancer: results from a randomized trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2001 , 51, 1246-55	4	166
11	Reduction of irradiated small bowel volume and accurate patient positioning by use of a bellyboard device in pelvic radiotherapy of gynecological cancer patients. <i>Radiotherapy and Oncology</i> , 2001 , 59, 87-93	5.3	50
10	Electronic portal image assisted reduction of systematic set-up errors in head and neck irradiation. <i>Radiotherapy and Oncology</i> , 2001 , 61, 299-308	5.3	93
9	Chest wall irradiation with MLC-shaped photon and electron fields. <i>International Journal of Radiation Oncology Biology Physics</i> , 2000 , 48, 1205-17	4	13
8	On-line set-up corrections during radiotherapy of patients with gynecologic tumors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2000 , 46, 499-506	4	57
7	Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. <i>Lancet, The</i> , 2000 , 355, 1404-11	40	1369
6	A quality control study of the accuracy of patient positioning in irradiation of pelvic fields. <i>International Journal of Radiation Oncology Biology Physics</i> , 1996 , 34, 697-708	4	71
5	High-precision prostate cancer irradiation by clinical application of an offline patient setup verification procedure, using portal imaging. <i>International Journal of Radiation Oncology Biology Physics</i> , 1996 , 35, 321-32	4	175
4	Multivariate analysis of survival in differentiated thyroid cancer: the prognostic significance of the age factor. <i>European Journal of Cancer & Clinical Oncology</i> , 1988 , 24, 331-7		72
3	Uterus467-478		
2	Uterus467-478		
1	Automated causal inference in application to randomized controlled clinical trials. <i>Nature Machine Intelligence</i> ,	22.5	1